Jeroen J.W.M. Janssen Department of Hematology VU University Medical Center Biography Publications Institution JoVE Articles Jeroen J.W.M. Janssen has not added a biography. If you are Jeroen J.W.M. Janssen and would like to personalize this page please email our Author Liaison for assistance. Publications Patient Satisfaction with Information on Oral Anticancer Agent Use Cancer Medicine. Jan, 2018 | Pubmed ID: 29168352 Omitting Cytogenetic Assessment from Routine Treatment Response Monitoring in Chronic Myeloid Leukemia is Safe European Journal of Haematology. Dec, 2017 | Pubmed ID: 29288559 Ponatinib in Chronic Myeloid Leukemia (CML): Consensus on Patient Treatment and Management from a European Expert Panel Critical Reviews in Oncology/hematology. Dec, 2017 | Pubmed ID: 29198338 Prevalence and Associated Factors of Medication Non-adherence in Hematological-oncological Patients in Their Home Situation BMC Cancer. Nov, 2017 | Pubmed ID: 29121889 Impact of Hospital Experience on the Quality of Tyrosine Kinase Inhibitor Response Monitoring and Consequence for Chronic Myeloid Leukemia Patient Survival Haematologica. Dec, 2017 | Pubmed ID: 28860340 Treatment Outcome in a Population-based, 'real-world' Cohort of Patients with Chronic Myeloid Leukemia Haematologica. Nov, 2017 | Pubmed ID: 28860339 Influence of WHO Versus ELN Advanced Phase Chronic Myeloid Leukemia Definitions on Overall Survival European Journal of Haematology. Oct, 2017 | Pubmed ID: 28718971 Dried Blood Spot Sampling of Nilotinib in Patients with Chronic Myeloid Leukaemia: a Comparison with Venous Blood Sampling The Journal of Pharmacy and Pharmacology. Oct, 2017 | Pubmed ID: 28643375 Nilotinib First-line Therapy in Patients with Philadelphia Chromosome-negative/BCR-ABL-positive Chronic Myeloid Leukemia in Chronic Phase: ENEST1st Sub-analysis Journal of Cancer Research and Clinical Oncology. Jul, 2017 | Pubmed ID: 28224300 Risk Factors for Relapse After Allogeneic Transplantation in Acute Myeloid Leukemia Haematologica. Jan, 2016 | Pubmed ID: 26721801 Study Protocol of the RAND-study: a Multicenter, Prospective Cohort Study Investigating Response and Adherence to Nilotinib Treatment in Chronic Myeloid Leukemia BMC Cancer. Apr, 2014 | Pubmed ID: 24712728 Imatinib Discontinuation in Chronic Phase Myeloid Leukaemia Patients in Sustained Complete Molecular Response: a Randomised Trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON) European Journal of Cancer (Oxford, England : 1990). Oct, 2013 | Pubmed ID: 23876833 High-dose Imatinib Versus High-dose Imatinib in Combination with Intermediate-dose Cytarabine in Patients with First Chronic Phase Myeloid Leukemia: a Randomized Phase III Trial of the Dutch-Belgian HOVON Study Group Annals of Hematology. Aug, 2013 | Pubmed ID: 23572137 Clinical Validation of Dried Blood Spot Sampling in Therapeutic Drug Monitoring of Ciclosporin A in Allogeneic Stem Cell Transplant Recipients: Direct Comparison Between Capillary and Venous Sampling Therapeutic Drug Monitoring. Feb, 2013 | Pubmed ID: 23296096 Chronic Myeloid Leukemia Lysate-loaded Dendritic Cells Induce T-cell Responses Towards Leukemia Progenitor Cells Immunotherapy. Apr, 2011 | Pubmed ID: 21463196 Schemi Di Metilazione in CD34 Positivi Leucemia Mieloide Cronica Crisi Blastomeri Haematologica. Jun, 2010 | Pubmed ID: 20421276 Valutazione Economica Di Posaconazolo Versus Fluconazolo Profilassi Nei Pazienti Con Graft - Versus - Host Disease (GVHD) Nei Paesi Bassi Annals of Hematology. Sep, 2010 | Pubmed ID: 20383504 A 51-year-old Male CML Patient with Progressive Hearing Loss, Confusion, Ataxia, and Aphasia During Imatinib Treatment American Journal of Hematology. Oct, 2009 | Pubmed ID: 19658186 Towards Cure of CML: Why We Need to Know More About CML Stem Cells? Current Stem Cell Research & Therapy. Sep, 2009 | Pubmed ID: 19492977 Reduced Supportive Capacity of Bone Marrow Stroma Upon Chemotherapy is Mediated Via Changes in Glycosaminoglycan Profile Matrix Biology : Journal of the International Society for Matrix Biology. Sep, 2007 | Pubmed ID: 17521897 Bone Marrow Stromal Proteoglycans Regulate Megakaryocytic Differentiation of Human Progenitor Cells Experimental Cell Research. Oct, 2004 | Pubmed ID: 15350537 Protocollo completo del campione e del midollo osseo di processo per misurare la malattia residua misurabile e cellule staminali leucemiche nella leucemia mieloide acuta Jacqueline Cloos*1,2, Jeffrey R. Harris*3, Jeroen J.W.M. Janssen1, Angele Kelder1, F. Huang3, Gerrit Sijm1, Maike Vonk1, Alexander N. Snel1, Jennifer R. Scheick1, Willemijn J. Scholten1, Jannemieke Carbaat-Ham1, Dennis Veldhuizen1, Diana Hanekamp1, Yvonne J.M. Oussoren-Brockhoff1, Gertjan J.L. Kaspers2,4, Gerrit J. Schuurhuis1, A. Kate Sasser3, Gert Ossenkoppele1 1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology JoVE 56386 Krebsforschung
Protocollo completo del campione e del midollo osseo di processo per misurare la malattia residua misurabile e cellule staminali leucemiche nella leucemia mieloide acuta Jacqueline Cloos*1,2, Jeffrey R. Harris*3, Jeroen J.W.M. Janssen1, Angele Kelder1, F. Huang3, Gerrit Sijm1, Maike Vonk1, Alexander N. Snel1, Jennifer R. Scheick1, Willemijn J. Scholten1, Jannemieke Carbaat-Ham1, Dennis Veldhuizen1, Diana Hanekamp1, Yvonne J.M. Oussoren-Brockhoff1, Gertjan J.L. Kaspers2,4, Gerrit J. Schuurhuis1, A. Kate Sasser3, Gert Ossenkoppele1 1Department of Hematology, VU University Medical Center, 2Pediatric Oncology/Hematology, VU University Medical Center, 3Janssen Research & Development, LLC, 4Princess Máxima Center for Pediatric Oncology JoVE 56386 Krebsforschung
